Frog skin is inspiration for potential diabetes treatment
ULSTER, Ireland New research has shown that the South American Pseudis paradoxa frog can actually stimulate the release of insulin and thus help millions of patients suffering from diabetes, according to published reports.
On the frog’s slimy skin is a peptide that is used to block it from infection, but has also been proven to increase insulin production in people with type 2 diabetes. In laboratory tests, researchers found that the paradoxical frog’s peptide, known as pseudin-2, increased release of insulin in cultured cells by 50 percent.
This would not be the first time a diabetes drug was created based on an animal’s secretions. Byetta is based on the saliva of an endangered lizard, the Gila monster of North America.
According to Yasser Abdel-Wahab, a senior lecturer in biomedical sciences at the University of Ulster, where the research took place, “We are at an exciting stage with this research,” he said. “We have tested a more potent synthetic version of the pseudin-2 peptide and have found that it has the potential for development into a compound for the treatment of Type 2 diabetes. Now we need to take this a step further and put our work into practice to try and help people with Type 2 diabetes.”
Rx program more expensive than chain store prescriptions
DENVER Rx Outreach, a Colorado program aimed at helping low-income people afford drugs for chronic diseases, was found to be more expensive for purchasing drugs than regular chain-store pharmacies.
A 90-day supply from a choice of 110 generics costs about $20 each, and three-dozen other drugs sell for $30 and $40. In contrast, Kmart’s program for a choice of 300 generic medications for a 90-day supply retails for $15, while Costco sells their prescriptions for about $10.66 and Walgreens sells them for about $12.99.
The program, Colorado Cares Rx, was unveiled this month by the Department of Health Care Policy and financing in partnership with Rx Outreach. The program was started by the state to develop a low-cost drug program, but the sponsors are finding it harder to compete with chain store rivals, based on pricing.
Officials claim growing pains, however. Rep. Alice Madden, D-Boulder, said “This is just a first step. We have to do more.”
FDA approves Abilify for teens
TOKYO and PRINCETON, N.J. The Food and Drug Administration has approved the Otsuka Pharmaceuticals and Bristol-Myers Squibb drug application for Abilify for the acute treatment of manic and mixed episodes associated with bipolar I disorder, with or without psychotic features in pediatric patients aged 10 to 17.
The approval is based on the results of a four-week study that compared Abilify to a placebo in treating pediatric patients with bipolar disorder I. Otsuka Pharmaceuticals sponsored the study.
“We are pleased that the FDA has approved Abilify to treat pediatric patients aged 10 to 17 years suffering from Bipolar I Disorder,” said Taro Iwamoto, Ph.D., chief executive officer, president and chief operating officer, Otsuka Pharmaceutical development and c commercialization. “The approval of this new indication for ABILIFY provides clinicians with expanded treatment options that can help address the therapeutic needs of this population.”